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Abstract
Introduction: Given the limited range of effective drug treatments for patients with schizophrenia,
increasing numbers of patients, often termed ‘treatment-resistant’ are prescribed clozapine. While
the induction of neutropenia or agranulocytosis by clozapine is well appreciated, other rare
potentially fatal adverse reactions may also occur including acute interstitial nephritis as reported in
this case.
Case presentation: A 57-year-old Caucasian woman with treatment-resistant chronic schizo-
phrenia developed acute renal failure following initiation of treatment with clozapine. The adverse
reaction occurred after only four doses of the drug had been administered (titrated from 12.5 to
25 mg per day). After clozapine had been withdrawn, the patient’s renal function returned to normal
with no other changes to medication. The patient had been exposed to clozapine about 4 years
previously when she had developed a similar reaction.
Conclusion: Renal reactions to clozapine are extremely rare but, if not recognized promptly, may
prove fatal. Psychiatrists need to be aware of this possible complication when clozapine is initiated.
Introduction
The dibenzodiazepine derivative, clozapine, is a so-called
‘atypical’ or second-generation antipsychotic that is widely
regarded as one of the more effective drug treatments for
schizophrenia. It can cause serious adverse effects on the
blood, including a potentially fatal neutropenia (around
2.7% of patients treated with clozapine), and its use is
therefore usually limited to treatment-resistant cases of
schizophrenia. Although a number of uncommon adverse
effects are recognised to occur with clozapine, including
hepatitis, pancreatitis, vasculitis and pneumonia [9], renal
adverse events are less well recognised. We report a case of
acute renal failure, assumed to be due to interstitial
nephritis that developed in a 57-year-old Caucasian
woman with treatment-resistant chronic schizophrenia
following initiation of treatment with clozapine. Although
renal complications of clozapine use are very rare, it is
essential that psychiatrists using clozapine are aware of the
potential for this adverse reaction in order to instigate
prompt treatment if necessary.
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Case presentation
The adverse reaction to clozapine occurred in a 57-year-old
married Caucasian woman with a long history of treat-
ment-resistant chronic schizophrenia (ICD10 F20) who
has required continuing care in hospital for many years,
due to the severity of her condition. She first developed
schizophrenia at around the age of 18 and has received
antipsychotic medication for almost 40 years. There is a
family history of schizophreniawithher son and amaternal
cousin both having the condition. Despite the recognized
advantages of treatingmany patients with schizophrenia in
community settings, her symptoms - both positive and
negative - have been resistant to a range of treatments and
as a consequence she has been in hospital since 1985.
Periodically, the patient can also exhibit challenging
behaviour that requires skilled nursing support; on occa-
sion, she has required nursing in the intensive psychiatric
care unit rather than the rehabilitation ward. The patient
has been prescribed many different antipsychotics over the
40year durationofher illness, including second-generation
(atypical) antipsychoticmedication, with unfortunately no
benefit to symptoms or functioning. A trial of clozapine in
June 2003was discontinued about amonth later following
development of acute renal failure, when she required
transfer to the general hospital unit. At that time, the renal
failure was attributed to clozapine by internal medicine
specialists, although the patient was also taking lithium at
this time, and developed secondary lithium toxicity with a
peak lithium of 2.2 mmol/L before all medication was
discontinued.
In November 2007, after a multidisciplinary case review, it
was decided that the patient might benefit from a retrial of
clozapine, especially given her failure to benefit from all
atypical antipsychotics available in the UK. This was
considered a reasonable strategy given that the adverse
renal effects seen previously when clozapine had been
introduced, were thought to have been caused, or exacer-
bated by, lithium carbonate. Given the severe and refractory
nature of the patient’s condition, and taking into account
the circumstances of the previous trial of clozapine, there
appeared compelling grounds for a reintroduction of
clozapine. The patient’s concomitant medication at the
time of the retrial was olanzapine 10 mg and levomepro-
mazine 75 mg at night and sodium valproate 1100 mg per
day; for acute exacerbations of psychosis, haloperidol 5 mg
IMwas available. This combination ofmedication had been
utilized for several months before the clozapine retrial,
without evidenceof adverse effects. Before the treatment trial
of clozapine, treatment with levomepromazine was discon-
tinued. Haematology and biochemistry blood results were
normal when checked 3 days before clozapinewas initiated.
Clozapine was started with a dose of 12.5 mg at night. On
day 2 of clozapine treatment (12.5 mg in the morning and
at night), the patient complained of feeling generally
unwell and on examination was tachycardic (115 beats
per minute) and pyrexial (37.5°C). On day 3 (12.5 mg
clozapine in the morning and at night), the patient
remained tachycardic and pyrexial (38.0°C). A urine
dipstick test showed a trace of protein and the presence
of red blood cells (RBCs) and the patient was presumed to
have a urinary tract infection and was commenced on
trimethoprim, after a urine (MSSU) sample had been sent
for bacteriology. On day 4, the patient’s pyrexia and
tachycardia persisted, and clozapine was stopped; a total of
five doses of clozapine had been given. Blood biochemistry
revealed a markedly elevated C-reactive protein (CRP)
of 197 mg/L; differential white cell count: lymphocytes
1.04 (1.3-3.5 × 109) and neutrophils 8.2 (2.0-7.5 × 109).
All other results were normal including creatinine
(87 μmol/L). Midstream specimen of urine showed scanty
pus cells and organisms, but no RBCs, and no growth. The
following day, trimethoprim was discontinued and amox-
icillin commenced for a suspected chest infection. The
raised temperature settled over the next few days, although
the patient remained tachycardic. Blood biochemistry on
day 8 showed CRP 138 mg/L, creatinine 126 μmol/L, and
an estimated glomerular filtration rate (eGFR) of 40 mL/
min/1.73 m2. Biochemistry results on day 9 were
creatinine 106 μmol/L, eGFR 50 mL/min/1.73 m2, and
erythrocyte sedimentation rate (ESR) 70 mm/hour. Amox-
icillin was discontinued after 5 days. Renal function
returned to normal over the next few days.
Discussion
Acute renal failure has been reported only rarely in
association with clozapine therapy [1-5]. Out of a total
of over 26,000 suspected adverse reactions to clozapine,
the UK Medicines and Healthcare products Regulatory
Agency (MHRA) has received only 10 reports of acute
interstitial nephritis and 31 reports of acute renal failure
(January 2009) [6]. In some of the cases [1,4], the
diagnosis had been confirmed by biopsy showing that
the renal failure had resulted from acute interstitial
nephritis. As psychiatrists and other clinicians will
appreciate, it is usually not possible to confirm diagnosis
by biopsy in most patients with behavioural disturbance
due to acute psychosis, despite the recognition that this
would normally be clinically desirable. Acute interstitial
nephritis is commonly caused by a drug hypersensitivity
reaction and, in this patient and other case reports, there
was a close temporal relationship between the start of
clozapine treatment and the development of interstitial
nephritis. In this case, the patient had been previously
exposed to clozapine and the rapid onset of the reaction
after just five doses of clozapine is consistent with a drug
hypersensitivity reaction. Following the withdrawal of
clozapine, the patient’s renal function returned to normal
with no other changes to medication.
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Treatment resistance in schizophrenia has been estimated
to be around 30% [7], and increasing numbers of patients
are being prescribed clozapine; for example, in the Scottish
Schizophrenia Outcomes Study [8], 40% of the cohort of
1015 patients was prescribed clozapine. Given the limited
efficacy of current antipsychotics, it is likely that increasing
numbers of patientsmay be treatedwith clozapine. Despite
advantages for somepatients, clinicians need to be aware of
the propensity of this drug to cause a wide range of adverse
reactions, some of which are quite rare. While 10 cases of
acute interstitial nephritis associated with clozapine have
been reported to the MHRA, far fewer cases appear to have
occurred with most other antipsychotics [6]. For example,
only one case has been reported for risperidone and
haloperidol [6], antipsychotics that have been widely
prescribed. As far as the authors are aware, there are no
reports of acute interstitial nephritis caused by other
atypical antipsychotics although there are reports of acute
renal failure occurring as a consequence of neuroleptic
malignant syndrome.
Conclusions
The purpose of this case report is to highlight to clinicians
the rare potential of clozapine to cause acute renal failure
and the importance of early recognition and treatment. As
adverse renal events occur rarely, there is a paucity of advice
for psychiatrists but the Maudsley Prescribing Guidelines
have a brief but useful section on the use of antipsychotics
in people with renal impairment and helpful guidance on
the use of clozapine in general [9]. Clinicians initiating
clozapine need to be aware of the possibility of a drug
induced renal adverse event and it is recommended that
baseline renal function is always assessed before clozapine
treatment is started, and monitored during the initiation
phase if necessary. Patients, like the one reported here, who
have had a previous trial of clozapine that was discon-
tinued due to a suspected adverse drug reaction, should
only be rechallenged with clozapine with due caution in
case some form of sensitization has developed. Psychia-
trists and psychiatric nurses should be watchful for the
following presenting features that may suggest a possible
drug induced acute interstitial nephritis: acute onset of
renal failure, usually within days of exposure to clozapine;
fever and tachycardia; skin rash; eosinophilia, elevated IgE
and CRP. Early involvement of a renal physician is
recommended if such a reaction is suspected.
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